2016
191TiP MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC
Peters S, Antonia S, Goldberg S, Heymach J, Kim E, Nakagawa K, Papadimitrakopoulou V, Mukhopadhyay P, McIntosh S, Rizvi N. 191TiP MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC. Journal Of Thoracic Oncology 2016, 11: s139-s140. DOI: 10.1016/s1556-0864(16)30300-8.Peer-Reviewed Original Research
2015
Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC
Rizvi N, Barlesi F, Brahmer J, Felip E, Forde P, Garassino M, Goldberg S, Vansteenkiste J, Jarkowski A, McIntosh S, Zhao L, Antonia S. Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC. Journal For ImmunoTherapy Of Cancer 2015, 3: p171. PMCID: PMC4646121, DOI: 10.1186/2051-1426-3-s2-p171.Peer-Reviewed Original Research